Yep the only thing that shareholders have to look forward to is more capital raises at ever lower prices. At least 4 years from royalties. So at least 2 more raises minimum. If the mosquito problem was so bad regulatory bodies would have fast tracked the product but there is simply zero interest in doing it indicating the situation is nowhere near as large a problem as we are led to believe. That was my take away. Watch the price continue lower, no reason to buy this for the next couple of years at least and then it will be a hard road as the existing products are still working. I think it is largely dead now, none of their partners have stepped up to invest either indicating that it is simply not a great investment, BASF also walked away for a reason.
The company has been a disaster for shareholders and this management looks to continue the tradition.
Ann: Envu collaboration on Flavocide for mosquito management, page-28
Add to My Watchlist
What is My Watchlist?
